STOCK TITAN

Guardant Health, Inc. - GH STOCK NEWS

Welcome to our dedicated page for Guardant Health news (Ticker: GH), a resource for investors and traders seeking the latest updates and insights on Guardant Health stock.

Guardant Health, Inc. (symbol: GH) is a pioneering biotechnology company headquartered in Redwood City, California. The company specializes in liquid-based cancer tests, providing innovative diagnostic tools for both clinical and research purposes. Guardant Health is renowned for its comprehensive liquid biopsy solutions, which offer non-invasive methods to access and sequence tumor DNA.

The company's flagship products include:

  • Guardant360 LDT: A liquid biopsy test that assists in treatment selection for advanced-stage cancer patients.
  • Guardant360 CDx: An FDA-approved companion diagnostic for several targeted therapies, ensuring precise treatment plans.
  • Guardant OMNI: A broad gene panel designed for immuno-oncology research, aiding in the understanding of cancer's genetic underpinnings.
  • Reveal: Launched in 2021, this tumor-agnostic molecular residual disease (MRD) test helps monitor cancer recurrence or residual disease at the molecular level.
  • Shield: Introduced in 2022, this lab-developed test offers a non-invasive screening option for colorectal cancer (CRC).

Guardant Health's cutting-edge technologies have been widely adopted by thousands of oncologists globally, benefiting tens of thousands of advanced cancer patients. The company has made significant strides in early cancer detection, with ongoing projects that promise to deliver profound impacts on patient care.

Financially, Guardant Health has raised over $500 million from prestigious investors such as Sequoia Capital, Khosla Ventures, Orbimed, and SoftBank. This substantial backing underscores the confidence in Guardant's potential to revolutionize cancer diagnostics and treatment.

In addition to its product offerings, Guardant Health provides research development services, including regulatory approval consultancy and clinical trial referrals. These services are designed to support the seamless integration of their diagnostic tools into clinical practice and research settings.

Stay updated with the latest news and developments about Guardant Health, Inc. as the company continues to push the boundaries of cancer diagnostics and treatment.

Rhea-AI Summary

Guardant Health (Nasdaq: GH) will release its financial results for Q1 2022 on May 5, 2022, after market close. A conference call for investors will follow at 1:30 p.m. PT / 4:30 p.m. ET. The call can be accessed via the company’s website, where an archive will be available post-event. Guardant Health specializes in precision oncology, offering advanced tests for cancer patients and driving initiatives to improve clinical outcomes and reduce healthcare costs.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.92%
Tags
conferences earnings
-
Rhea-AI Summary

Guardant Health (NASDAQ: GH) announced promising data from its investigational Guardant SHIELD multi-cancer assay. This blood test analyzes approximately 20,000 epigenomic biomarkers to detect early-stage cancers, specifically colorectal, lung, pancreatic, and bladder cancers, which account for over 200,000 deaths annually in the U.S. The assay demonstrated a 90% sensitivity for stages I and II colorectal cancer and 87% for lung cancer, with high accuracy in identifying tumor tissue types. These results suggest potential to significantly improve cancer screening rates and save lives.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.5%
Tags
none
-
Rhea-AI Summary

Guardant Health has announced a partnership with Epic, enhancing access to its cancer tests for over 250 million patients. This integration allows healthcare providers to electronically order Guardant tests, including Guardant SHIELD for colorectal cancer screening, and access results seamlessly. The collaboration aims to simplify workflows for clinicians, improving patient care by ensuring quick access to critical test results. The integration is expected to be completed in Q3 2023, promoting the adoption of Guardant's precision oncology offerings across diverse healthcare settings.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.9%
Tags
partnership
Rhea-AI Summary

Guardant Health (Nasdaq: GH) responded to a lawsuit from Illumina challenging its ownership of intellectual property related to blood tests. Guardant claims the lawsuit is an attempt to suppress competition, following its concerns about the antitrust implications of Illumina's acquisition of Grail. Despite legal challenges, Guardant remains committed to its mission of developing cancer screening tests. The company maintains that their long-term supply agreement with Illumina is intact and that they will vigorously defend their intellectual property rights.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.77%
Tags
none
-
Rhea-AI Summary

Guardant Health, Inc. (Nasdaq: GH) has received regulatory approval from the Japanese Ministry of Health, Labour and Welfare for its Guardant360® CDx test, which profiles tumor mutations in patients with advanced solid tumors. The test will identify patients with microsatellite instability-high (MSI-High) tumors eligible for Keytruda® and Opdivo®. This approval enhances the company's commitment to improving cancer care through innovative blood-based diagnostics, following a prior approval for NSCLC in December 2021.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.06%
Tags
none
-
Rhea-AI Summary

Guardant Health (Nasdaq: GH) announced it will present new findings from its next-generation Guardant SHIELD assay at the AACR Annual Meeting from April 8-13, 2022. The data highlights the assay's ability to detect early-stage cancers and accurately identify their tissue of origin. Co-CEO AmirAli Talasaz emphasized the company's commitment to enhancing cancer care. The presentation will cover various studies, including a highly-sensitive cell-free DNA assay and real-world effectiveness of CDK4/6 inhibitors for breast cancer.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.39%
Tags
conferences
Rhea-AI Summary

Guardant Health, Inc. (NASDAQ: GH) announced that Palmetto GBA has granted coverage for its Guardant360 TissueNext™ test under the existing local coverage determination for next-generation sequencing of solid tumors. This tissue-based test aims to assist oncologists in identifying advanced cancer patients who may benefit from biomarker-informed treatments. Medicare will cover the test for fee-for-service patients with advanced solid tumor cancers. This marks an expansion of coverage for Guardant's tests and enhances access to genomic profiling for patients with advanced cancer.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.58%
Tags
none
-
Rhea-AI Summary

Guardant Health reported strong Q4 2021 results with revenue of $108 million, a 38% increase year-over-year. For the full year, revenue reached $374 million, up 30%. Clinical tests surged by 48% to 25,600, while biopharma tests rose 36% to 6,600. Gross profit improved to $74.7 million with a 69% gross margin. Despite increased operating expenses of $172.9 million, the net loss narrowed to $90.9 million. The company expects 2022 revenue between $460 million and $470 million.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.01%
Tags
-
Rhea-AI Summary

Guardant Health, a leading precision oncology company, will participate virtually in several key investor conferences in February and March 2022. The conferences include:

  • 11th Annual SVB Leerink Global Healthcare Conference on February 16 at 9:00 a.m. PT.
  • Citi 2022 Healthcare Conference on February 24 at 11:45 a.m. PT.
  • Cowen 42nd Annual Health Care Conference on March 8 at 10:30 a.m. PT.

Live and archived webcasts will be available on the company's website. Guardant Health aims to enhance cancer care through its innovative tests and analytics.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.41%
Tags
conferences
Rhea-AI Summary

Guardant Health, Inc. (NASDAQ: GH) announced it will release its financial results for Q4 and the full year 2021 on February 23, 2022, after market close. A conference call will follow at 1:30 p.m. PT (4:30 p.m. ET). The event can be streamed live from the company’s website, with an archive available post-event. Guardant Health specializes in precision oncology, offering advanced diagnostic tests like Guardant360 and Guardant Reveal to enhance cancer care.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.37%
Tags
conferences earnings

FAQ

What is the current stock price of Guardant Health (GH)?

The current stock price of Guardant Health (GH) is $38.1 as of January 13, 2025.

What is the market cap of Guardant Health (GH)?

The market cap of Guardant Health (GH) is approximately 4.5B.

What does Guardant Health, Inc. specialize in?

Guardant Health specializes in liquid-based cancer tests, providing non-invasive diagnostic tools for clinical and research use.

What are the main products offered by Guardant Health?

Guardant Health offers Guardant360 LDT, Guardant360 CDx, Guardant OMNI, Reveal, and Shield, which are various liquid biopsy tests for cancer detection and treatment selection.

What is Guardant360 CDx?

Guardant360 CDx is an FDA-approved companion diagnostic test used to guide targeted cancer therapies.

How does Guardant Health support cancer research?

Guardant Health aids cancer research through products like Guardant OMNI and services such as regulatory approval consultancy and clinical trial referrals.

What is the significance of the Reveal test?

Reveal is a tumor-agnostic molecular residual disease (MRD) test that helps monitor cancer recurrence or residual disease at the molecular level.

What is the purpose of the Shield test?

The Shield test is a non-invasive liquid biopsy for colorectal cancer (CRC) screening.

Who are some of the major investors in Guardant Health?

Guardant Health has received investments from Sequoia Capital, Khosla Ventures, Orbimed, and SoftBank.

Where is Guardant Health, Inc. headquartered?

Guardant Health, Inc. is headquartered in Redwood City, California.

What is the Guardant360 LDT test used for?

Guardant360 LDT is used for treatment selection in patients with advanced-stage cancer.

How does Guardant Health contribute to early cancer detection?

Guardant Health contributes to early cancer detection through its pioneering products and ongoing research in liquid biopsy technologies.
Guardant Health, Inc.

Nasdaq:GH

GH Rankings

GH Stock Data

4.53B
117.76M
4.57%
105.24%
6.68%
Diagnostics & Research
Services-medical Laboratories
Link
United States of America
PALO ALTO